ROYALTY PARTICIPATION AGREEMENT between THERAVANCE, INC. and ELAN CORPORATION PLC Dated as of May 12, 2013 Article I DEFINITIONS AND INTERPRETATION Article II SALE OF BENEFICIAL INTERESTRoyalty Participation Agreement • May 17th, 2013 • Elan Corp PLC • Pharmaceutical preparations • New York
ROYALTY PARTICIPATION AGREEMENT, dated as of May 12, 2013 (this "Agreement"), between THERAVANCE, INC., a Delaware corporation ("Seller"), and ELAN CORPORATION PLC, an Irish public limited company ("Purchaser"; and each of Seller and Purchaser, a "Party" and together, the "Parties").
EXHIBIT D. PURCHASER ROYALTY AGREEMENTRoyalty Participation Agreement • March 19th, 2021 • Nutralife Biosciences, Inc • Dairy products • Florida
This Royalty Participation Agreement (the “Royalty Agreement”) is made and effective as of the day set forth on the signature page hereto by and between NutraLife BioSciences, Inc., a Florida corporation (“NutraLife”), PhytoChem Technologies, Inc. (“PhytoChem”), a Florida corporation (NutraLife and PhytoChem are collectively referred to herein as the “Company”), and Kahn Family Limited PT II (the “Purchaser”). The Company and the Purchaser are referred to herein collectively as the “Parties”, or individually as a “Party”.
ContractRoyalty Participation Agreement • May 5th, 2020
EX-10.2 3 exhibit102.htm EXHIBIT 10.2 ROYALTY PARTICIPATION AGREEMENT This Royalty Participation Agreement (the “Royalty Agreement”) is entered into by and between Auriga Laboratories, Inc., a Delaware corporation, located at 5284 Adolfo Road Camarillo, California 93012, and each of its subsidiaries (collectively, the “Company”) and Prospector Capital Partners II, LLC, a Delaware limited liability company, located at 3112 Windsor Road, Suite A-137, Austin, Texas 78703 (the “Investor”). RECITALS WHEREAS, the Company is in the business of commercializing, licensing, and developing of prescription pharmaceutical products; and WHEREAS, Company desires to issue and sell to the Investor, and the Investor has agreed to purchase from the Company a Senior Secured Convertible Promissory Note in a principal aggregate amount of $287,500 (the “Principal Financing Amount”), pursuant to that certain Senior Secured Convertible Note Purchase Agreement and Senior Secured Convertible Promissory Note betw
ROYALTY PARTICIPATION AGREEMENTRoyalty Participation Agreement • February 3rd, 2021 • Replicel Life Sciences Inc. • Biological products, (no disgnostic substances) • British Columbia
THIS ROYALTY PARTICIPATION AGREEMENT (this "Agreement"), made and entered into as of January 22, 2021 (the "Effective Date"), by and between:
RECITALSRoyalty Participation Agreement • May 11th, 2006 • In Veritas Medical Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York
ROYALTY PARTICIPATION AGREEMENTRoyalty Participation Agreement • June 13th, 2008 • Auriga Laboratories, Inc. • Pharmaceutical preparations • Texas
This Royalty Participation Agreement (the “Royalty Agreement”) is entered into by and between Auriga Laboratories, Inc., a Delaware corporation, located at 5284 Adolfo Road Camarillo, California 93012, and each of its subsidiaries (collectively, the “Company”) and Prospector Capital Partners II, LLC, a Delaware limited liability company, located at 3112 Windsor Road, Suite A-137, Austin, Texas 78703 (the “Investor”).
AMENDMENT NO. 1 TO ROYALTY PARTICIPATION AGREEMENTRoyalty Participation Agreement • April 24th, 2008 • In Veritas Medical Diagnostics, Inc. • Surgical & medical instruments & apparatus
This Amendment No. 1 to Royalty Participation Agreement (this "Agreement"), is made as of April 21, 2008, among the parties listed on the signature page hereto (the “RPA Holder”), and In Veritas Medical Diagnostics, Inc. (the "Company").
EXHIBIT G: PLEDGOR ROYALTY AGREEMENTRoyalty Participation Agreement • March 19th, 2021 • Nutralife Biosciences, Inc • Dairy products • Florida
This Royalty Participation Agreement (the “Pledgor Royalty Agreement”) is made and effective as of the day set forth on the signature page hereto by and between NutraLife BioSciences, Inc., a Florida corporation (“NutraLife”), PhytoChem Technologies, Inc. (“PhytoChem”), a Florida corporation (NutraLife and PhytoChem are collectively referred to herein as the “Company”), and Brenda Hamilton, an individual (“Pledgor). The Company and the Pledgor are referred to herein collectively as the “Parties”, or individually as a “Party”.
ROYALTY PARTICIPATION AGREEMENTRoyalty Participation Agreement • February 19th, 2008 • Auriga Laboratories, Inc. • Pharmaceutical preparations • Texas
This Royalty Participation Agreement (the “Royalty Agreement”) is entered into by and between Auriga Laboratories, Inc., a Delaware corporation, located at 5284 Adolfo Road Camarillo, California 93012, and each of its subsidiaries (collectively, the “Company”) and Prospector Capital Partners, LLC, a Delaware limited liability company, located at 3112 Windsor Road, Suite A-137, Austin, Texas 78703 (the “Investor”).
